Abstract
Aminolevulinic acid (ALA)-based photodynamic therapy (PDT) has been successfully employed in the treatment of certain tumours. Porphyrins endogenously generated from ALA induce tumour regression after illumination with light of an appropriate wavelength. The aim of this work was to compare porphyrin production from ALA and sensitivity to photodynamic treatment in a tumour/normal cell line pair. We employed the HB4a cell line from normal mammary luminal epithelium and its counterpart transfected with the oncogen H-Ras (VAL/12 Ras). After 3 h of exposure to ALA, HB4a-Ras cells produce a maximum of 150 ng porphyrins per 105 cells whereas HB4a produce 95 ng porphyrins per 105 cells. In addition, HB4a-Ras cells show a plateau of porphyrin synthesis at 1 mM whereas HB4a porphyrins peak at the same concentration, and then decrease quickly. This higher porphyrin synthesis in the tumorigenic cell line does not lead to a higher response to the photodynamic treatment upon illumination. Lethal doses 50, LD50, determined by MTT assay were 0.015 J cm−2 and 0.039 J cm−2 for HB4a and HB4a-Ras respectively after 3 h exposure to 1 mM ALA. The conclusion of this work is that a tumour cell line obtained by transfection of the Ras oncogene, although producing higher porphyrin synthesis from ALA, is more resistant to ALA-PDT than the parental non-tumour line, however the mechanism is not related to photosensitiser accumulation, but very likely to cell survival responses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ALA:
-
5-aminolevulinic acid
- PDT:
-
photodynamic therapy
- ALAPDT:
-
ALA-based PDT
- PpIX:
-
protoporphyrin IX
References
T. J. Dougherty, Photodynamic Therapy - new approaches, Semin. Surg. Oncol., 1989, 5, 6–16.
C. Kelty, N. Brown, M. Reed, R. Ackroyd, The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis, Photochem. Photobiol. Sci., 2002, 1, 158–68.
R. Van Hillesberg, J. Van der Berg, W. Kort, O. Terpstra, J. Wilson, Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats, Gastroenterology, 1992, 103, 647–51.
N. Navone, C. Polo, A. Frisardi, A. Batlle, Mouse mammary carcinoma PBGase and hydroxymethylbilane synthetase, Comp. Biochem. Physiol. B, 1991, 98, 67–1.
J. Bos, Ras oncogenes in human cancer: a review, Cancer Res., 1989, 49, 4682–689.
P. Rodriguez-Viciana, O. Tetsu, K. Oda, J. Okada, K. Rauen, F. McCormick, Cancer targets in the Ras pathway, Cold Spring Harbor Symp. Quant. Biol., 2005, 70, 461–467.
A. C. Stamps, S. C. Davies, J. Burman, M. J. O’Hare, Analysis of proviral integration in human mammary epithelial cell lines immortalised by retroviral infection with a temperature-sensitive SV40 T-antigen construct, Int. J. Cancer, 1994, 57, 1–10.
D. Rusnak, K. Affleck, S. Cockerill, C. Stubberfield, R. Harris, M. Page, The Characterization of Novel, Dual ErbB-2/EGFR, Tyrosine Kinase Inhibitors: Potential Therapy for Cancer, Cancer Res., 2001, 61, 7196–7203.
F. Denizot, R. Lang, Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability, J. Immunol. Methods, 1986, 89, 271–277.
S. Iinuma, S. S. Farshi, B. Ortel, T. Hasan, A mechanistic study of cellular photoactivation with 5-aminolevulinic acid-induced porphyrins, Br. J. Cancer, 1994, 70, 21–28.
O. Lowry, N. Rosebrough, L. Farr, R. Randall, Protein measurement with the folin phenol reagents, J. Biol. Chem., 1951, 193, 265–275.
G. Li, M. Szewczuk, L. Raptis, J. Johnson, G. Weagle, R. Pottier, J. Kennedy, Rodent fibroblast model for studies of response of malignant cells to exogenous 5-aminolevulinic acid, Br. J. Cancer, 1999, 80, 676–84.
A. Deora, T. Win, B. Vanhaesebroeck, H. M. Lander, A redox-triggered ras-effector interaction. Recruitment of phosphatidylinositol 39-kinase to Ras by redox stress, J. Biol. Chem., 1998, 273, 29923–29928.
Z. Tong, G. Singh, A. J. Rainbow, The role of the p53 tumor suppressor in the response of human cells to photofrin-mediated photodynamic therapy, Photochem. Photobiol., 2000, 71, 201–210.
D. Zaak, M. Kriegmair, H. Stepp, H. Stepp, R. Baumgartner, R. Oberneder, P. Schneede, S. Corvin, D. Frimberger, R. Knuchel, A. Hofstetter, Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies, Urology, 2001, 57, 690–694.
S. A. Friesen, G. O. Hjortland, S. J. Madsen, H. Hirschberg, O. Engebraten, J. M. Nesland, Q. Peng, 5-Aminolevulinic acid–based photodynamic detection and therapy of brain tumors (review), Int. J. Oncol., 2002, 21, 577–582.
W. J. Piotrowski, J. Marczak, A. Nawrocka, A. Antczak, P. Gorski, Inhalations of 5-ALA in photodynamic diagnosis of bronchial cancer, Monaldi Arch. Chest. Dis., 2004, 61, 86–93.
P. Baas, M. Triesscheijn, S. Burgers, P. van Pel, F. Stewart, M. Aalders, Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid, Chest, 2006, 129, 718–24.
Q. Peng, J. Moan, T. Warloe, J. M. Nesland, C. Rimington, Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary carcinoma, Int. J. Cancer, 1992, 52, 433–443.
A. Casas, H. Fukuda, A. M. Batlle, Tissue distribution and kinetics of endogenous porphyrins synthesized after topical application of ALA in different vehicles, Br. J. Cancer, 1999, 81, 13–18.
J. Moan, L. W. Ma, V. Iani, On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters, Int. J. Cancer, 2001, 92, 139–143.
K. Svanberg, D. L. Liu, I. Wang, S. Andersson-Engels, U. Stenram, S. Svanberg, Photodynamic therapy using intravenous delta-aminolaevulinic acid-induced protoporphyrin IX sensitisation in experimental hepatic tumours in rats, Br. J. Cancer, 1996, 74, 1526–1533.
Z. Ji, G. Yang, V. Vasovic, B. Cunderlikova, Z. Suo, J. Nesland, Q. Peng, Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines, J. Photochem. Photobiol., B, 2006, 84, 213–220.
K. Lang, K. Bolsen, W. Stahl, T. Ruzicka, H. Sies, P. Lehmann, C. Fritsch, The 5-aminolevulinic acid-induced porphyrin biosynthesis in benign and malignant cells of the skin, J. Photochem. Photobiol., B, 2001, 65, 29–34.
K. Rittenhouse-Diakun, H. Van Leengoed, J. Morgan, E. Hryhorenko, G. Paszkiewicz, J. E. Whitaker, A. R. Oseroff, The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA), Photochem. Photobiol., 1995, 61, 523–528.
D. Grebenova, H. Cajthamlova, J. Bartosova, J. Marinov, H. Klamova, O. Fuchs, Z. Hrkal, Selective destruction of leukaemic cells by photo-activation of 5-aminolaevulinic acid-induced protoporphyrin-IX, J. Photochem. Photobiol., B, 1998, 47, 74–81.
A. Casas, C. Perotti, H. Fukuda, A. M. Batlle, Photodynamic therapy of activated and resting lymphocytes and its antioxidant adaptive response, Lasers Med. Sci., 2002, 17, 42–50.
E. Hryhorenko, A. Oseroff, J. Morgan, K. Rittenhouse-Diakun, Deletion of alloantigen-activated cells by aminolevulinic acid–based photodynamic therapy, Photochem. Photobiol., 1999, 69, 560–565.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dedicated to the memory of Dr Susana Afonso.
Rights and permissions
About this article
Cite this article
Rodriguez, L., DiVenosa, G., Batlle, A. et al. Response to ALA-based PDT in an immortalised normal breast cell line and its counterpart transformed with the Ras oncogene. Photochem Photobiol Sci 6, 1306–1310 (2007). https://doi.org/10.1039/b704235c
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1039/b704235c